USP and Public Policy

usp public policy
Left
usp public policy

Refine Your Search

All Results
USP Comment Letter: Submitted to Congress on Cannabis Administration and Opportunity Act (CAOA) Discussion (2021)
USP greatly appreciate the opportunity to provide feedback on the Cannabis Administration and Opportunity Act (CAOA) Discussion Draft. Learn More
USP Comment Letter: Submitted to the New York State Department of Health on Cannabinoid Hemp Proposed Rulemaking (2021)
USP appreciates the opportunity to comment on the State of New York’s proposed rulemaking, “Addition of Part 1005 to Title 10 NYCARR (Cannabinoid Hemp).” Learn More
USP Comment Letter: Submitted to FDA on Nitrosamines Guidance (2020)
USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA or the Agency) Guidance for Industry, Control of Nitrosamine Impurities in Human Drugs. Learn More
USP Comment Letter: Submitted to FDA on Cannabis in Clinical Research Draft Guidance (2020)
USP appreciates the opportunity to comment on FDA’s draft guidance Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research. Learn More
USP Comment Letter: Submitted to CDC-NIOSH on Managing Hazardous Drug Exposures (2020)
USP appreciates the opportunity to comment on the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) draft document, Managing… Learn More
USP Comment Letter: Submitted to FDA on Importation of Prescription Drugs - Proposed Rule (2020)
USP appreciates the opportunity to provide comments to the Food and Drug Administration (FDA or Agency) on the “Importation of Prescription Drugs” proposed rule. Learn More
USP Comment Letter: Submitted to FDA on FDA/FTC Workshop on a Competitive Marketplace for Biosimilars (2020)
USP appreciates this opportunity to present our comments on the competitive marketplace for biosimilars. Learn More
USP Comment Letter: Submitted to FDA on Draft Guidance, “Compounding Animal Drugs from Bulk Drug Substances (2020)
USP appreciates the opportunity to provide comments on FDA’s draft guidance, “Compounding Animal Drugs from Bulk Drug Substances.” Learn More
USP Comment Letter: Submission to ITC on Investigation No. 332-580; COVID-19 Related Goods: The U.S. Industry, Market, Trade, and Supply Chain Challenges (2020)
USP supports more transparency from the pharmaceutical industry to support a more resilient supply chain to help ensure the continued availability of safe, quality medicines. Learn More
USP Comment Letter: Submitted to FDA on Clinical Immunogenicity Insulin Draft Guidance (2020)
USP appreciates the opportunity to comment on FDA’s draft guidance, “Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products.” Learn More

Document Classification

Topics